Standout Papers

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, ... 2021 2026 2022 2024385
  1. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial (2021)
    Paul M. Ridker, Matt Devalaraja et al. The Lancet

Citation Impact

2 from Science/Nature 62 standout
Sub-graph 1 of 20

Citing Papers

The Role of Pro-Inflammatory Cytokines in the Pathogenesis of Cardiovascular Disease
2024 Standout
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
2024 Standout
3 intermediate papers

Works of Matt Devalaraja being referenced

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
2021 Standout
Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
2020

Author Peers

Author Molecular Biology Nephrology Hematology Immunology Surgery Last Decade Papers Cites
Matt Devalaraja 121 55 68 183 123 8 483
Arezou Mashak 15 34 19 340
Elena Zaccaria 3 2 4 10 6 309
Cuizhu He 2 12 853
Florian Moder 13 4 344
Thomas M. York 2 41 339

All Works

Loading papers...

Rankless by CCL
2026